From owner-repertoires@net.bio.net Sat Nov 07 22:00:00 1998 Path: biosci!biosci!not-for-mail From: BIOSCI Administrator Newsgroups: bionet.molecules.repertoires Subject: BIOSCI/bionet miniFAQ & Fundraiser Date: 8 Nov 1998 10:35:22 -0800 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 236 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <199810281000.CAA16251@net.bio.net> NNTP-Posting-Host: net.bio.net (LAST REVISION: 30-JUL-95) This BIOSCI "miniFAQ" is designed to answer the questions that come up the *most frequently*. The main BIOSCI FAQ (Frequently Asked Questions) is accessible on the World Wide Web at URL http://www.bio.net/. If you can not find an answer to your question in this or other documentation, the BIOSCI technical support staff answers e-mail queries sent to biosci-help@net.bio.net We can only answer questions about the use of the newsgroups and mailing lists. We unfortunately do not have the staff to do Internet information searches or answer scientific questions. Please post those to the appropriate BIOSCI/bionet newsgroups. Contents: -------- 0) BIOSCI NEEDS YOUR SUPPORT!! 1) Using the WWW to access the BIOSCI/bionet newsgroups. 2) What to do about "spams," i.e., junk mail, ads, etc. 3) Examples of subscribing and unsubscribing to the mailing lists. 4) The BIOSCI user address and research interest directory. 0) BIOSCI NEEDS YOUR SUPPORT!! ------------------------------ BIOSCI's government funding has been expended, and we are now operating solely from advertising revenue that we have raised from our Web site at http://www.bio.net/. We need just a few minutes of your time to help us serve you. You can do two important things which will take very little time for you individually and will immensely help us continue to help you. First, please use our WWW system at http://www.bio.net/ to access the archives. You can post or reply to messages via your Web browser as described in item #1 below. Your usage helps attract sponsors. If you contact any of our sponsors, please be sure to thank them for supporting BIOSCI. It is critical for them to get this feedback if they are to continue their sponsorship for the long term. Second, if you work for a company or organization that provides products or services of interest to the biology community, please pass this message on to your marketing or marketing communications department or other appropriate group. Please ask them to help support BIOSCI by sponsoring our Web site and explain the uses and benefits of the system to the biology community. If they are interested, they can then contact us for further information at our tech support address, biosci-help@net.bio.net. 1) Using the WWW to access the BIOSCI/bionet newsgroups. -------------------------------------------------------- As of 10 December 1995, all BIOSCI/bionet full newsgroups are accessible through the World Wide Web (WWW) at URL http://www.bio.net. One can read and reply publicly or privately to both recent postings and archived messages through one's Web browser if it is configured properly to send e-mail. Each newsgroup is equipped with its own WAIS index. The main BIOSCI home page also has access to the BIO-JOURNALS Table of Contents database WAIS index and the BIOSCI user address database described in another item further below. 2) What to do about "spams," i.e., junk mail, ads, etc. ------------------------------------------------------- BIOSCI is a set of parallel USENET newsgroups (the "bionet" groups), mailing lists, and a hypermail archive at URL http://www.bio.net/. The same postings are distributed on all media (except for a small number of mailing-list-only groups at net.bio.net). Unfortunately it is becoming a despicable practice on the Internet (by a few people out to make a fast buck) to do automated mass postings to thousands of newsgroups and mailing lists. These attempts to grab free advertising are refered to as "spams" in the usual, somewhat boneheaded, net terminology. USENET is more susceptible to this practice, and many spams originate on the USENET groups and then are passed on to the mailing lists. However, spammers also get lists of mailing addresses and hit these too, so neither medium is immune. What should you do personally if you get junk mail? --------------------------------------------------- Just delete it and move on without reading it further. Filing a protest is becoming increasingly useless because spammers are often disguising the addresses where the messages are sent from. Unless you really understand Internet mail systems, your attempt at protest by sending replies to the message will often end up being sent to the address of an innocent person that the spammer is victimizing. What can BIOSCI/bionet do to protect its newsgroups? ---------------------------------------------------- The only solution currently available is to moderate the newsgroup. If this newsgroup is already moderated, then you are in good shape. Moderation protects the USENET distribution from about 95% of the spams that are being sent to date and protects the mailing lists completely. Moderation means, however, that someone has to take the time to review each message before it goes out. We have set up software here that simply allows the moderator to forward to an address at net.bio.net messages that (s)he wishes to have distributed. This takes no more time than that needed to read the message and pass it on, say about 1 min. per message. Most newsgroups currently have a discussion leader who is responsible for their newsgroup. The discussions leaders and their e-mail addresses are listed in the BIOSCI Information Sheet which is available on the Web at http://www.bio.net/. If a newsgroup is being hit with too many junk postings, please contact the discussion leader for that group and see if there is interest in moderating the group. Please do not assume that by simply posting a complaint to the newsgroup itself, anyone on the BIOSCI staff will act on your complaint. With close to 100 newsgroups to run, the BIOSCI staff has to rely on the discussion leaders of each newsgroup to report problems directly to us at biosci-help@net.bio.net. We will moderate any of our newsgroups if the discussion leader tells us that the readership of the group wishes to do so and if a moderator is willing to do the work. For most BIOSCI/bionet groups, this entails only a few minutes of work each day. Moderating a newsgroup will resolve probably 95% of the junk postings on the USENET distribution. Unfortunately there are easy ways for determined spammers to override the moderation mechanism on USENET, but we can protect our e-mail subscribers from unwanted postings if the newsgroup is moderated. You can also access our newsgroups over the WWW at URL http://www.bio.net. While this Web interface will not stop spammers from trying to post to the groups, this will give you yet another way, besides using USENET news, to keep the junk out of your personal mail files. For those of you with local USENET news systems, the Web interface will also give you faster access to new newsgroups and recent postings. 3) Examples of subscribing and unsubscribing to the mailing lists. ------------------------------------------------------------------ PLEASE NOTE: The BIOSCI management does NOT act on subscription/unsubscription requests that are posted improperly to the newsgroups and mailing lists. People who do this only bother everyone on the lists to no avail. Please be sure to follow the proper procedures below. Gory details are in the BIOSCI Information sheets on the Web at http://www.bio.net. Below we give an example utilizing the METHODS-AND-REAGENTS list at both of our two BIOSCI sites: Users in the Americas and Pacific Rim countries who use the BIOSCI ------------------------------------------------------------------ node at computer net.bio.net: ---------------------------- A) Determine the "listname" which is the <=8 character mail address ^^^^^^^^^^^^^ for the group. These can be found in the BIOSCI Info. Sheet. For the METHODS-AND-REAGENTS group the mailing address is methods@net.bio.net. The listname is the portion of the address to the left of the @ sign, i.e., "methods". The listname is used with the "subscribe" and "unsubscribe" commands illustrated below. B) Mail all commands in the body of a mail message addressed to biosci-server@net.bio.net. Do NOT send commands to the newsgroup posting addresses! Leave the Subject: line blank, any text on it will be ignored. C) In the body of your message put one or more of the following commands with an "end" command on the last line, e.g., subscribe methods unsubscribe methods end Do NOT put your e-mail address or other text on these lines. The server only allows you to cancel your subscription if the address on your mail header matches the address on our mailing list. Please ask for help at biosci-help@net.bio.net if your address has changed, e.g., if you know you are on the list but the server tells you that you are not a member. Users in Europe, Africa, and Central Asia who use the BIOSCI node at -------------------------------------------------------------------- computer daresbury.ac.uk (also known as dl.ac.uk): ------------------------------------------------- To subscribe and unsubscribe to/from the BIOSCI lists, you need to specify the full USENET newsgroup name with "bionet-news." prepended. The USENET newsgroup names are listed in the BIOSCI Information sheet on the Web at http://www.bio.net/. For the METHODS-AND-REAGENTS list the USENET newsgroup name is bionet.molbio.methds-reagnts, thus the appropriate commands are sub bionet-news.bionet.molbio.methds-reagnts unsub bionet-news.bionet.molbio.methds-reagnts These commands are included in a message addressed to mxt@dl.ac.uk, NOT to the newsgroup mailing addresses. As usual, include the text in the body of the message as text on the Subject: line is ignored. To unsubscribe from all the lists at the UK node, use unsub bionet-news Please note that if the address in the list is different than the one in your mail message header, you will not be able to unsubscribe by this method. If you have problems, please mail biosci@daresbury.ac.uk. 4) The BIOSCI user address and research interest directory. ----------------------------------------------------------- Please take this opportunity to add your name, address, and research interest information to the BIOSCI User Address Database if you have not already done so. You can fill out the address form directly through our Web page at URL http://www.bio.net/adrform.html. The address database is reindexed nightly for WWW access (the URL is http://www.bio.net/). If you are not directly on the Internet but can reach it by e-mail, please use our waismail server to access the user directory. waismail use is described above. You can also request a user address form by e-mail from biosci-help@net.bio.net. Please check your database entry from time-to-time to see if your address information is still up-to-date. Because of our limited personnel resources, we ask that you resubmit a *complete* form to revise your entry; we only replace complete entries and do not have resources to edit old forms. From owner-repertoires@net.bio.net Sat Nov 07 22:00:00 1998 Path: biosci!biosci!not-for-mail From: Thomas Newsgroups: bionet.molecules.repertoires Subject: p3-antibody Date: 8 Nov 1998 10:41:06 -0800 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 23 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <362C7400.DE38D292@medizin.uni-koeln.de> Reply-To: Thomas.Pfitzner@medizin.uni-koeln.de NNTP-Posting-Host: net.bio.net Hi, I would like to know, if anybody has an Antibody against the p3 protein of the filamentous bacteriophage M13. Please let me know. Thomas Pfitzner University of Cologne Dept. I of Internal Medicine Laboratory of Immunotherapy LFI, E4, R703 Joseph-Stelzmann-Str. 9 D-50931 KOELN Germany Phone: +49 (0) 221-478-5993 / -4418 Fax: +49 (0) 221-478-6383 E-Mail: Thomas.Pfitzner@medizin.uni-koeln.de From owner-repertoires@net.bio.net Fri Nov 13 22:00:00 1998 Path: biosci!biosci!not-for-mail From: John Collins Newsgroups: bionet.molecules.repertoires Subject: Group head position available at Cosmix molecular biologicals GmbH Date: 14 Nov 1998 06:27:32 -0800 Organization: Cosmix molecular biologicals GmbH Lines: 125 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <6278n6$81c@mserv1.dl.ac.uk> Reply-To: jco@GBF.DE NNTP-Posting-Host: net.bio.net Group head position available at Cosmix molecular biologicals GmbH, Salary dependent on experience ( DM 90 0000 minimum p.a. with additional profit-dependent bonuses ). Mascheroder Weg 1b, D 38124 Braunschweig, Germany. FAX: +49 531 6181202; Tel: Professor John Collins, CEO, +49 531 6181 200 Please send enquiries and/or applications, with CV and a brief resume of current work, to Professor Collins at the above address. The candidate should have experience in phage display and other cloning and gene expression technologies, or high through-put screening. He or she should have interest in leading a dynamic team dealing with service contracts and the development of innovative applications of the phage-display technology. ************************ A brief overview of the company follows (see also http://www.cosmix.de ) The company was founded by John Collins at the end of 1997 and has recently started to make inroads into the market, with contracts from both academia, the pharmaceutical industry and diagnostics companies - a market which is expanding rapidly. We have developed a broad range of specialized phage display libraries which can be used effectively with our propriety technology. Acquisition and performance of contract work is intellectually demanding since it is based on an empirical technology, where the range of application is only limited by the innovative selection strategies which are under continuous development. Our work, in this respect, does not therefore differ significantly from an academic research environment, especially since we encourage academic collaborations for our in house development projects. The core technology: cosmix-plexing(TM) Cosmix molecular biologicals GmbH offers a service for the isolation of peptidic and protein structures with unique properties, such as cyclic peptides and antibodies with exquisite specificity and high avidity. For the numerous areas of application see below., The core technology, cosmix-plexing is a novel system for continuously generating huge diversity during the selection procedure, e.g., in combination with phage-display technology. In this respect it is a truly evolutive technique, differing from others, in that recombination takes place within the hypervariable region of the gene encoding the selectable ligand variants, thus maximizing target-oriented diversity. Since affinity selection is carried out in vitro additional criteria can be demanded, e.g. acid or temperature stability, absence of cross-reaction to similar targets, the use of impure targets or the isolation of ligands binding to neighbouring epitopes on a target. Antibodies can be produced to "self" proteins which cannot be obtained by immunisation. We deliver the enriched clones, data on the enriched clone sequences and ranking of affinity to the target, and on request can provide additional services The client pays a small "bench" fee and a final "success" fee only if the experiment has delivered clones according to his specification. Applications of high-affinity ligands are to be found increasingly in the development of: - agonists and antogonists of biological response modifiers - diagnostic kits - enzyme inhibitors - research reagents - tissue-targetting vectors - histological reagents - competitors for HTS and in epitope mapping to identify candidate natural ligands (genome projects). In addition the technique can also be used for enzyme evolution. Mastering the uncertainties of empirical methods with improved technology: Nobody finds phage-display to be a trivial technique: This is one of the reasons, we see, for the need of a professional service in this area (cf., oligonucleotide-synthesis, DNA sequencing and monoclonal antibodies). Our novel development takes much of the uncertainty out of the phage-display technology, which of its very nature must remain an empirical method. We find that the method greatly increases the number of positive experiments. In addition the ligands we isolate bind several orders of magnitude more strongly than those obtained with the initial libraries. The whole procedure, however, takes less than six weeks, and many selections can be run in parallel so that we can offer a rapid reliable service at a very competitive price.=20 Confidentiality and exclusivity: Working in our own laboratories we can offer the highest confidentiality and in addition ensure the client that contracts on a particular library/target combination will only be carried out for a single client. Although this may mean disappointing some later potential clients we believe this is a valuable code of ethics. We also provide a custom library synthesis service for special applications, e.g. where a biased cassette is inserted into an existing library to produce an extension library in which the powerful recombination technique can be applied to both extensions, e.g. for targetting specific receptors; proline-rich for SH3-domains; tyrosine-rich for targetting oligosaccharides.. We can extend our service to whole project planning with milestones, or arrange collaborative liaisons to take over a regular part of your development research, e.g. selection of highly specific antibodies or other ligands for diagnostic kits. The team: An essential aspect of our development is to stay at the forefront of the methodological developments with cutting-edge technology. Our key to this is the initial team: John Collins (coinventor, with Peter Roettgen, of Cosmix-plexing) is Professor for Genetics at the University of Braunschweig, and Head of the Dept. of Applied Genetics at the GBF - the National Center for Biotechnologyy in Braunschweig, currently freed from most of these obligations to set up the Company. He has 25 years experience in the application of gene technology to biotechnological problems and was inventor, with Barbara Hohn, of the powerful cosmid cloning system. His previous work included the isolation of strong human elastase inhibitors with phage-display technology. Michael Szardenings has an excellent track record in the area of protein design in the GBF, Berlin and Uppsala and was the first person to isolate G-protein-coupled receptor ligands via phage-display. He has validated the use of cosmix-plexing with a mouse Fab antibody library on numerous targets. A strong liaison to Professor Jan Engberg, Royal School of Pharmacy, Copenhagen, was also extremely instrumental in establishing the practicality of the methodology. Having a lead investor, Buchler GmbH, Braunschweig allows us to concentrate on work in our service and development labs. From owner-repertoires@net.bio.net Fri Nov 13 22:00:00 1998 Path: biosci!biosci!not-for-mail From: andy.zaayenga@bigfoot.com (Andy Zaayenga) Newsgroups: bionet.molecules.repertoires Subject: Announce: HTS Automation Meeting Date: 14 Nov 1998 06:20:30 -0800 Organization: ICGNetcom Lines: 253 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <364bb26f.9201945@nntp.ix.netcom.com> NNTP-Posting-Host: net.bio.net The Laboratory Robotics Interest Group December 1998 Meeting High Throughput Screening Date: Tuesday, December 8, 1998 Place: Raritan Valley Community College Advanced Technology Communication Center, Somerville, NJ 08876 Itinerary: Social Period with Vendor Participation, Food & Refreshments and Poster Session, Lobby -  4:00 to 7:00 PM Presentations and Discussion, Auditorium - 7:00 to 9:15 PM Pre-Registration: Requested, not required. Registering will allow us to more accurately gauge seating requirements and refreshment needs. Indicate names of attendees and company affiliation. Email: andy.zaayenga@lab-robotics.org Phone: (732)302-1038 Fax: (732)302-9080 Agenda:  An exciting agenda is planned for this meeti d around High Throughput Screening.  During the Social Period which will feature food and refreshments, there will be a HTS Vendor's Exhibition.  Four presentations with discussion will follow.  Members interested in presenting a poster are encouraged to do so.  Open career positions at your company may be announced or posted.  There is no fee to attend the meeting. Exhibiting Vendors: Beckman Coulter Bio-Tek Instruments CCS/Packard Instruments Cetek CRS Robotics EG&G Wallac EMAX Solution Partners GeneVac Ltd./BioVac Gilson Inc. Hudson Control Group IGEN Leap Technologies LJL Biosystems Marsh Biomedical Products Matrix Technologies Millipore Corporation Molecular Devices Nalge Nunc Int' PE Biosystems - Tropix Pierce Chemical Polyfiltronics / Whatman Inc. Robbins Scientific Scitec Inc. Skatron The Automation Partnership Tecan TekCel Corporation Titertek Instruments Tomtec Torcon Instruments Inc. Zymark Corporation ______________________________________________________ Presentation:  Automation of the assay development phase of drug discovery Damien Dunnington (1), Anthony Lozada (1), Hsiu-Yu Tseng (1), Paul Taylor (2) and Frances Stewart (2) 1. Hoechst Marion Roussel, Route 202-206, Bridgewater NJ 08807 2. SmithKline Beecham Pharmaceuticals, 709 Swedeland Road, King of Prussia PA 19406 The early phase of drug discovery, beginning with information and ending with lead compounds, has been re-engineered in recent years to accommodate advances in combinatorial chemistry and genomics. However, the reengineering has not been uniform and a disproportionate effort has been devoted to the screening phase, with relatively little attention to the assay development and hit follow-up stages where substantial bottlenecks persist. As new technologies such as miniaturization and fluorescence are introduced, the gap between an assay conceived by a disease group and the requirements for automated high throughput screening is becoming ever wider. The assay development and reformatting bottleneck has inspired an automated appr problem. This approach combines established design-of-experiments techniques with robotics and interfacing software, with the ultimate goal of assay configuration in a virtual lab environment and direct interfacing with robotics for execution. Examples will be presented to illustrate the impact of these approaches on assay configuration, robustness and hit detection, and progress toward a fully automated process will be discussed. ______________________________________________________ Presentation:  A Fully Automated Processing System for Fractionating Natural Products Robert Corr Scientist, Natural Products Discovery Pfizer Central Research We have designed, built, and integrated a fully automated robotic system that processes crude plant extracts. This system includes bar-coding and weighing, solvent addition and homogenizing, solid phase extraction, evaporation, reweighing, pipetting, and a track robot to move samples through the system. ______________________________________________________ Presentation:  HTS and Lead Optimization Using FLIPR Joseph Gunnet, Ph.D. Principal Scientist, Endocrine Therapeutics The R.W. Johnson Pharmaceutical Research Institute, Rt. 202, Raritan, NJ 08869 The identification of functional agonists and antagonists for some G-protein coupled receptors (GPCRs) can be done by monitoring intracellular calcium mobilization. FLIPR (Fluorometric Imaging Plate Reader; Molecular Devices Corp.) allows GPCR-induced calcium responses to be accurately and reliably quantitated in an entire 96 well plate. With its CCD camera, FLIPR collects data at rate sufficient to follow the magnitude and time course of GPCR activation in each well. The large amount of information gathered from each well may be analyzed to simply identify hits in HTS or may be analyzed in more detail to optimize leads and ensure receptor-mediated activity. While most of the varibles in using FLIPR are the same as for any 96 well liquid handling system and fluorescent-based assay, performing HTS with FLIPR poses some unique nd opportunities. We have worked through some of these biological, mechanical and data analysis issues and have successfully run HTS with FLIPR. Improvements in FLIPR hardware and data processing will soon be available and will expand the utility of an already useful instrument. ______________________________________________________ Presentation:  Validation of Engineered Cell-Based Screens for G Protein-Coupled Receptors E. William Radany, Ph.D. Business Manager Stratagene G protein-coupled receptors and receptor tyrosine kinases are important targets for drug discovery. High throughput screening (HTS) assays based on ligand binding to these targets may yield biased results depending on the cellular environment in which the cloned receptor resides. The use of engineered cell lines of defined signalling properties with specific receptors provides new tools for HTS assays and the the study of orphan receptors. This presentation will focus on the development of discovery platforms based on reporter gene technology utilizing cells with specific signalling pathways. ______________________________________________________ Group Update:  There were over 500 attendees to our June Vendors Night!   Ope Odusan from Wyeth-Ayerst Research won the business card drawing and received a handsome rosewood LRIG pen desk set.  We hold a similar drawing at every meeting.   John Wetzel from Synaptic Pharmaceuticals won a Pyrex storage set in the Corning Costar drawing.  Joe Kwasnoski from 3-Dimensional Pharmaceuticals won a Corelle Thermoserver, also from Corning Costar.   The winner of the CD player in the EMAX drawing was Guy Schiehser from Wyeth-Ayerst Research. The Society for Biomolecular Screening hosted us from September 20-24 at their 4th Annual Conference and Exhibition in Baltimore, MD.   We had a very successful week with hundreds of visitors and 138 new member signups! Valuable input came in from interested parties across the U.S. and overseas.   There is a lot of interest in forming chapters in Massachusetts, Californ   If you can help us by being a local representative, please step up.  We held business card drawings every day.  Janet Hartman Johnson (Boehringer Ingelheim), Mojgan Abousleiman (R.W. Johnson PRI), and Howard Miller (Pharmacia & Upjohn) all won rosewood LRIG pen desk sets.  Thank you, SBS! The Discussion Mailing List debuted on October 12.   It became an immediate hit and now has over 300 subscribers and many interesting dialogues on hardware, software, and methodology.  More information may be found at: http://lab-robotics.org/discussion.htm. ISLAR graciously provided us with a table during the conference October 19-21.  We welcome 211 new members.  Jennifer McMackin (Merck) and Dr. Dave Tapolczay (Cambridge Combinatorial) won rosewood pen sets in the business card drawings.  We identified prospective board members for the Boston, San Francisco, and RTP chapters.  Thank you, Zymark! We are actively forming the Boston and Bay Area LRIG Chapters.  Research Triangle Park and Europe are potential candidates.  If you are interested in helping form these chapters by serving on the local board or energizing your peers, please contact us. We are moving to an email-only meeting notification system.  If you are receiving this mailer in paper form, please send your email address to andy.zaayenga@lab-robotics.org ______________________________________________________ Mailing Sponsor:  LJL BioSystems  is a proud sponsor of LRIG activities. LJL BioSystems (www.ljlbio.com) designs, produces, and markets instrumentation, reagents, microplates and services that accelerate and enhance the drug discovery process. Our flagship product, Analyst HTS Assay Detection System, is a four-mode analyzer specifically designed for the HTS environment. Food & Refreshment Sponsor:  IGEN International Inc. develops detection platforms utilizing ORIGEN® technology, electrochemiluminescence.  Flexible formats allow quantification of specific interactions between two molecules (including: quantitation of analytes, mRNA, Kp's of receptor-liga nzyme-substrate activities, interaction of DNA binding-proteins with DNA).  Combining its homogeneous format with a flow cell approach improves sensitivity and precision, while streamlining assay automation. ______________________________________________________ For more information contact: Executive Chair: Dennis France dennis.france@pharma.novartis.com (908) 277-5328 Novartis Pharmaceuticals Corporation Secretary: Andy Zaayenga andy..zaayenga@tekcel.com (732) 302-1038 TekCel Corporation Analytical Chemistry Chair and Treasurer: William Haller bhaller@ompus.jnj.com (908) 218-6341 Ortho-McNeil High Throughput Screening Chair: John Babiak, Ph.D. babiakj@war.wyeth.com (732) 274-4788 Wyeth-Ayerst Research Agricultural Applications Chair: Sharon Reed reeds@pt.cyanamid.com (609) 716-2905 American Cyanamid Data Management Chair: Steve Fillers, Ph.D. steve_fillers@biogen.com (617) 679-2657 Biogen Inc. ______________________________________________________ Directions: The Raritan Valley Community College campus lies at the crossroads of Central New Jersey, with Routes 22, 202 and 206 and Interstates 287 and 78 just minutes away. The College is situated on the north side of Route 28 in North Branch. On line directions and hotel information at: http://lab-robotics.org/1298.htm ______________________________________________________ Visit the Laboratory Robotics Interest Group homepage at: http://lab-robotics.org From owner-repertoires@net.bio.net Fri Nov 13 22:00:00 1998 Path: biosci!biosci!not-for-mail From: "Wang, Kevin" Newsgroups: bionet.molecules.repertoires Subject: Post-Doctoral Position available at Parke-Davis Pharm. Co. Date: 14 Nov 1998 06:42:15 -0800 Organization: Parke-Davis Pharmaceutical Research Lines: 40 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <6278n6$85c@mserv1.dl.ac.uk> Reply-To: Kevin.Wang@WL.COM NNTP-Posting-Host: net.bio.net Cloning and Characterization of a Protease related apoptosis inhibitor gene: A joint postdoctoral position was created between Departments of Neuroscience and Molecular Biology at Parke-Davis Pharmaceutical Research in our effort to understand molecular mechanism of apoptosis. We are looking for a strong postdoc to clone and characterize a protease-related apoptois gene and its protein product. Beside working in a stimulating research environment, the candidate will interact with other pharmaceutical scientists from different disciplines and get familiarized with industrial research. The candidate should have a Ph.D. in Molecular Biology/Biochemistry or related areas with a strong molecular biology and biochemistry background. Experience with apoptosis study is highly desirable, but not required. Highly motivated applicants should submit their curriculum vitae, a brief summary of their research accomplishments/interests and a list of 3 references to Human Resources Department, Parke-Davis Pharmaceutical Research, 2800 Plymouth Rd, Ann Arbor, MI 48105. The PD facility is only 2 miles east of the medical school campus of the University of Michigan (Ann Arbor). We offer very competitive salary ($35, 500 /yr starting salary) with a one-time Relocation Lump Sum ($5,000). The contract is for two year with a potential 3rd yr. extension. PD is an EEO employer. Please contact with cover letter and C.V. with name of 3 references by fax or e-mail to: Kevin Wang , Ph.D. Sr. Research Associate, Neuroscience Therapeutics Co-Chair, Far East Scientific Opportunities Committee Parke-Davis Pharmaceutical Research, Ann Arbor, MI48105 Tel. (734)-622-7132; Fax. (734)-622-7178; 622-2755 e-mail: kevin.wang@wl.com Adjunct Assistant Professor of Pharmacology University of Michigan School of Medicine http://www.med.umich.edu/pharm/wang.html From owner-repertoires@net.bio.net Fri Nov 13 22:00:00 1998 Path: biosci!biosci!not-for-mail From: Ingemar Nilsson Newsgroups: bionet.molecules.repertoires Subject: 96 glass deepwell microtiter plates? Date: 14 Nov 1998 06:38:22 -0800 Organization: Astra Haessle Lines: 19 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <6278n6$83c@mserv1.dl.ac.uk> Reply-To: ingemar.nilsson@HASSLE.SE.ASTRA.COM NNTP-Posting-Host: net.bio.net > > Dear subscribers, > > I am currently looking for 96 deepwell microtiter plates made of glass. Is > anyone aware if there is something on the market? > If so I would be very pleased if you reply to > > Ingemar Nilsson > > Combinarorial Chemistry > Astra Haessle > Sweden > email: ingemar.nilsson@hassle.se.astra.com > From owner-repertoires@net.bio.net Fri Nov 13 22:00:00 1998 Path: biosci!biosci!not-for-mail From: "Amy L. Dasch" Newsgroups: bionet.molecules.repertoires Subject: Conference Announcement and Call for Proposals Date: 14 Nov 1998 06:32:50 -0800 Organization: Cambridge Healthtech Institute Lines: 61 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <6278n6$82c@mserv1.dl.ac.uk> Reply-To: adasch@HEALTHTECH.COM NNTP-Posting-Host: net.bio.net First Announcement and Call for Proposals Cambridge Healthtech Institute's Third Annual CHEMOINFORMATICS May 3-5, 1999 Hotel Renaissance Washington, D.C. Computational Methodologies can significantly change the design, screening and optimization of drug leads. In an ever increasing effort to reduce the need for random screening, drug developers are looking to chemoinformatic-based strategies for mining and interpretation of screening data, structure or activity based modeling or the identification of leads as well as for the greater understanding of drug-target interaction. One of the most interesting aspects of the use of metric-based computational methods of creating library subsets that meet the defined criteria of similarity or diversity. Advances in virtual screening track computational capability, as computers improve, so does screening speed and complexity. Parameters such as structure, function or chemical space allows for nearly limitless array of screening options. The use of screening data for development decision making is predicated on the management and interpretation of the data. Extraction of information from the data is the vital link between theoretical design and drug candidate. Finally, it is the integration of iterative results from computation to activity that drives the cycle forward. Researchers involved in projects that address issues related to chemoinformatics are encouraged to submit a proposed title, and if possible, a short summary, for consideration for an oral presentation for this meeting. If you have suggestions for speakers that you would be interested in hearing at this meeting, their name, as well as contact information, would also be welcomed. Session topics to be covered will include: Virtual Chemistry Integration of Archival Data Diversity Metrics Structurally-based Diversity Searches or Comparisons Functionally-based Diversity Searches or Comparisons Virtual Database Screening Extraction of Information from High Throughput Screening Results Integration of Screening Results with Structural-based Design Efforts Application of Chemoinformatics to Lead Optimization Integration of Biological Activity Data Personnel Recruitment for Chemoinformatics Please submit abstract by fax or e-mail to: Amy L. Dasch, Conference Director fax: 617-630-1325 e-mail: adasch@healthtech.com deadline for submission November 2, 1998 Cambridge Healthtech Institute is pleased to present our annual Chemoinformatics conference in conjunction with three other conferences : High-Throughput Screening for Drug Discovery, and lab automation. From owner-repertoires@net.bio.net Fri Nov 13 22:00:00 1998 Path: biosci!biosci!not-for-mail From: Andrew Wallace Newsgroups: bionet.molecules.repertoires Subject: Problems posting to bionet.molecules.repertoires Date: 14 Nov 1998 07:00:57 -0800 Organization: Queens University Belfast Lines: 18 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <6278n6$86c@mserv1.dl.ac.uk> Reply-To: a.wallace@qub.ac.uk NNTP-Posting-Host: net.bio.net There appears to be a technical problem in posting messages to this newsgroup at the moment, resulting in the delayed distribution or even disappearance of messages in some cases. If you have posted a message to this newsgroup within the last 48 hours and have not seen it appear yet, then please send it again. Andrew ------------------------------------------------------------------ Andrew Wallace, Ph.D School of Biology and Biochemistry, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7BL, Northern Ireland (UK). Tel. : +44 (0)7074 226373 Fax : +44 (0)7074 426373 Email: a.wallace@qub.ac.uk or andrew_wallace@hotmail.com WWW : http://www.qub.ac.uk/bb/awpage/wallace.html From owner-repertoires@net.bio.net Sat Nov 21 22:00:00 1998 Path: biosci!biosci!not-for-mail From: EVA Newsgroups: bionet.molecules.repertoires Subject: WEB Date: 22 Nov 1998 06:59:29 -0800 Organization: Goya Servicios Telematicos SA Lines: 6 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <738pgi$hmb$66@relay.eunet.es> NNTP-Posting-Host: net.bio.net http://www.paisvirtual.com/informatica/diseno_web/ALPHAECO/ From owner-repertoires@net.bio.net Sat Nov 21 22:00:00 1998 Path: biosci!biosci!not-for-mail From: Kim Takita Newsgroups: bionet.molecules.repertoires Subject: Materials Discovery Survey is now Online Date: 22 Nov 1998 06:57:48 -0800 Organization: The Knowledge Foundation, Inc. Lines: 26 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <6278n6$89b@mserv1.dl.ac.uk> Reply-To: kmtakita@KNOWLEDGEFOUNDATION.COM NNTP-Posting-Host: net.bio.net Combinatorial Chemistry The Knowledge Foundation is conducting an industry survey on the Usage of New Materials Discovery Technologies. The survey can now be filled out on-line at our website: http://www.knowledgefoundation.com/survey_combi.html The purpose of the survey is to identify & compare leading methodologies, determine current usage/industry evaluation of the combinatorial chemistry approach and technological hurdles. All who participate in the survey will receive a copy of the results. The survey is easy and quick to complete. Please take a moment to visit our online survey page. Please feel free to contact me - email: kmtakita@knowledgefoundation.com with any questions. ------------------------------------------------------------------------ ---------- Kim Takita Vice President The Knowledge Foundation, Inc. 101 Merrimac Street Boston, MA 02114 Phone: 617-367-7979 ext. 202 Fax: 617-367-7912 E-Mail: kmtakita@knowledgefoundation.com http://www.knowledgefoundation.com From owner-repertoires@net.bio.net Sat Nov 21 22:00:00 1998 Path: biosci!biosci!not-for-mail From: Laboratory Robotics Interest Group Newsgroups: bionet.molecules.repertoires Subject: Announce: HTS Automation Meeting Date: 22 Nov 1998 07:40:38 -0800 Organization: The Laboratory Robotics Interest Group Lines: 271 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <6278n6$99b@mserv1.dl.ac.uk> Reply-To: zaayenga@LAB-ROBOTICS.ORG NNTP-Posting-Host: net.bio.net The Laboratory Robotics Interest Group December 1998 Meeting High Throughput Screening Date: Tuesday, December 8, 1998 Place: Raritan Valley Community College Advanced Technology Communication Center, Somerville, NJ 08876 Itinerary: Social Period with Vendor Participation, Food & Refreshments and Poster Session, Lobby - 4:00 to 7:00 PM Presentations and Discussion, Auditorium - 7:00 to 9:15 PM Pre-Registration: Requested, not required. Registering will allow us to more accurately gauge seating requirements and refreshment needs. Indicate names of attendees and company affiliation. Email: andy.zaayenga@lab-robotics.org Phone: (732)302-1038 Fax: (732)302-9080 Agenda: An exciting agenda is planned for this meeting centered around High Throughput Screening. During the Social Period which will feature food and refreshments, there will be a HTS Vendor's Exhibition. Four presentations with dis low. Members interested in presenting a poster are encouraged to do so. Open career positions at your company may be announced or posted. There is no fee to attend the meeting. Exhibiting Vendors: Beckman Coulter Bio-Tek Instruments CCS/Packard Instruments Cetek CRS Robotics EG&G Wallac EMAX Solution Partners GeneVac Ltd./BioVac Gilson Inc. Hudson Control Group IGEN Leap Technologies LJL Biosystems Marsh Biomedical Products Matrix Technologies Millipore Corporation Molecular Devices Nalge Nunc Int' PE Biosystems - Tropix Pierce Chemical Polyfiltronics / Whatman Inc. Robbins Scientific Scitec Inc. Skatron The Automation Partnership Tecan TekCel Corporation Titertek Instruments Tomtec Torcon Instruments Inc. Zymark Corporation ______________________________________________________ Presentation: Automation of the assay development phase of drug discovery Damien Dunnington (1), Anthony Lozada (1), Hsiu-Yu Tseng (1), Paul Taylor (2) and Frances Stewart (2) 1. Hoechst Marion Roussel, Route 202-206, Bridgewater NJ 08807 2. SmithKline Beecham Pharmaceuticals, 709 Swedeland Road, King of Prussia PA 19406 The early phase of drug discovery, beginning with information and ending with lead compounds, has been re-engineered in recent years to accommodate advances in combinatorial chemistry and genomics. However, the reengineering has not been uniform and a disproportionate effort has been devoted to the screening phase, with relatively little attention to the assay development and hit follow-up stages where substantial bottlenecks persist. As new technologies such as miniaturization and fluorescence are introduced, the gap between an assay conceived by a disease group and the requirements for automated high throughput screening is becoming ever wider. The assay development and reformatting bottleneck has inspired an automated approach toward streamlining and ultimately eliminating this problem. This approach combines established design-of-experiments techniques with robotics and interfacing software, with the ultimate g vironment and direct interfacing with robotics for execution. Examples will be presented to illustrate the impact of these approaches on assay configuration, robustness and hit detection, and progress toward a fully automated process will be discussed. ______________________________________________________ Presentation: A Fully Automated Processing System for Fractionating Natural Products Robert Corr Scientist, Natural Products Discovery Pfizer Central Research We have designed, built, and integrated a fully automated robotic system that processes crude plant extracts. This system includes bar-coding and weighing, solvent addition and homogenizing, solid phase extraction, evaporation, reweighing, pipetting, and a track robot to move samples through the system. ______________________________________________________ Presentation: HTS and Lead Optimization Using FLIPR Joseph Gunnet, Ph.D. Principal Scientist, Endocrine Therapeutics The R.W. Johnson Pharmaceutical Research Institute, Rt. 202, Raritan, NJ 08869 The identification of functional agonists and antagonists for some G-protein coupled receptors (GPCRs) can be done by monitoring intracellular calcium mobilization. FLIPR (Fluorometric Imaging Plate Reader; Molecular Devices Corp.) allows GPCR-induced calcium responses to be accurately and reliably quantitated in an entire 96 well plate. With its CCD camera, FLIPR collects data at rate sufficient to follow the magnitude and time course of GPCR activation in each well. The large amount of information gathered from each well may be analyzed to simply identify hits in HTS or may be analyzed in more detail to optimize leads and ensure receptor-mediated activity. While most of the varibles in using FLIPR are the same as for any 96 well liquid handling system and fluorescent-based assay, performing HTS with FLIPR poses some unique issues and opportunities. We have worked through some of these biological, mechanical and data analysis issues and have successfully run HTS with FLIPR. Improvements in FLIPR hardwar processing will soon be available and will expand the utility of an already useful instrument. ______________________________________________________ Presentation: Validation of Engineered Cell-Based Screens for G Protein-Coupled Receptors E. William Radany, Ph.D. Business Manager Stratagene G protein-coupled receptors and receptor tyrosine kinases are important targets for drug discovery. High throughput screening (HTS) assays based on ligand binding to these targets may yield biased results depending on the cellular environment in which the cloned receptor resides. The use of engineered cell lines of defined signalling properties with specific receptors provides new tools for HTS assays and the the study of orphan receptors. This presentation will focus on the development of discovery platforms based on reporter gene technology utilizing cells with specific signalling pathways. ______________________________________________________ Group Update: There were over 500 attendees to our June Vendors Night! Ope Odusan from Wyeth-Ayerst Research won the business card drawing and received a handsome rosewood LRIG pen desk set. We hold a similar drawing at every meeting. John Wetzel from Synaptic Pharmaceuticals won a Pyrex storage set in the Corning Costar drawing. Joe Kwasnoski from 3-Dimensional Pharmaceuticals won a Corelle Thermoserver, also from Corning Costar. The winner of the CD player in the EMAX drawing was Guy Schiehser from Wyeth-Ayerst Research. The Society for Biomolecular Screening hosted us from September 20-24 at their 4th Annual Conference and Exhibition in Baltimore, MD. We had a very successful week with hundreds of visitors and 138 new member signups! Valuable input came in from interested parties across the U.S. and overseas. There is a lot of interest in forming chapters in Massachusetts, California, North Carolina, and Europe. If you can help us by being a local representative, please step up. We held business card drawings every day. Janet Hartman Johnson (Boehringer Ingelh and Howard Miller (Pharmacia & Upjohn) all won rosewood LRIG pen desk sets. Thank you, SBS! The Discussion Mailing List debuted on October 12. It became an immediate hit and now has over 300 subscribers and many interesting dialogues on hardware, software, and methodology. More information may be found at: http://lab-robotics.org/discussion.htm. ISLAR graciously provided us with a table during the conference October 19-21. We welcome 211 new members. Jennifer McMackin (Merck) and Dr. Dave Tapolczay (Cambridge Combinatorial) won rosewood pen sets in the business card drawings. We identified prospective board members for the Boston, San Francisco, and RTP chapters. Thank you, Zymark! We are actively forming the Boston and Bay Area LRIG Chapters. Research Triangle Park and Europe are potential candidates. If you are interested in helping form these chapters by serving on the local board or energizing your peers, please contact us. We are moving to an email-only meeting notification system. If you are receiving this mailer in paper form, please send your email address to andy.zaayenga@lab-robotics.org ______________________________________________________ Mailing Sponsor: LJL BioSystems is a proud sponsor of LRIG activities. LJL BioSystems (www.ljlbio.com) designs, produces, and markets instrumentation, reagents, microplates and services that accelerate and enhance the drug discovery process. Our flagship product, Analyst HTS Assay Detection System, is a four-mode analyzer specifically designed for the HTS environment. Food & Refreshment Sponsor: IGEN International Inc. develops detection platforms utilizing ORIGEN® technology, electrochemiluminescence. Flexible formats allow quantification of specific interactions between two molecules (including: quantitation of analytes, mRNA, Kp's of receptor-ligand pairs, enzyme-substrate activities, interaction of DNA binding-proteins with DNA). Combining its homogeneous format with a flow cell approach improves sensitivity and precision, while streamlining omation. ______________________________________________________ For more information contact: Executive Chair: Dennis France dennis.france@pharma.novartis.com (908) 277-5328 Novartis Pharmaceuticals Corporation Secretary: Andy Zaayenga andy.zaayenga@tekcel.com (732) 302-1038 TekCel Corporation Analytical Chemistry Chair and Treasurer: William Haller bhaller@ompus.jnj.com (908) 218-6341 Ortho-McNeil High Throughput Screening Chair: John Babiak, Ph.D. babiakj@war.wyeth.com (732) 274-4788 Wyeth-Ayerst Research Agricultural Applications Chair: Sharon Reed reeds@pt.cyanamid.com (609) 716-2905 American Cyanamid Data Management Chair: Steve Fillers, Ph.D. steve_fillers@biogen.com (617) 679-2657 Biogen Inc. ______________________________________________________ Directions: The Raritan Valley Community College campus lies at the crossroads of Central New Jersey, with Routes 22, 202 and 206 and Interstates 287 and 78 just minutes away. The College is situated on the north side of Route 28 in North Branch. On line directions and hotel information at: http://lab-robotics.org/1298.htm ______________________________________________________ Visit the Laboratory Robotics Interest Group homepage at: http://lab-robotics.org From owner-repertoires@net.bio.net Mon Nov 23 22:00:00 1998 Path: biosci!biosci!not-for-mail From: "Dr. Wendy A. Warr" Newsgroups: bionet.molecules.repertoires Subject: Report on Chemistry and The Internet Date: 24 Nov 1998 10:54:02 -0800 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 20 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <73bvl5$qpn$1@mserv2.dl.ac.uk> NNTP-Posting-Host: net.bio.net Some of you may have seen my FREE report about the Chemistry and the Internet conference held in Irvine in September. If you haven't, do visit http://www.warr.com/chemint.html You may want to print the report for reading later - it runs to about 40 pages - but there are no graphics and access should be fast. Apologies for duplicate messaging. Wendy -- Dr Wendy A Warr Wendy Warr & Associates, 6 Berwick Court Holmes Chapel, Cheshire CW4 7HZ, England Tel/fax +44 (0)1477 533837 wendy@warr.com http://www.warr.com From owner-repertoires@net.bio.net Wed Nov 25 22:00:00 1998 Path: biosci!biosci!not-for-mail From: Marta Fanciullo Newsgroups: bionet.molecules.repertoires Subject: supercomputing or artificial intelligence in combinatorial chemistry Date: 26 Nov 1998 01:14:39 -0800 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 11 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <73epvi$d0u$1@mserv2.dl.ac.uk> NNTP-Posting-Host: net.bio.net Please, I need to know if there are some applications of supercomputing or artificial intelligence in combinatorial chemistry field. thank you, Marta Fanciullo Tecnofarmaci S.C.p.A. From owner-repertoires@net.bio.net Wed Nov 25 22:00:00 1998 Path: biosci!biosci!not-for-mail From: Huichen Newsgroups: bionet.molecules.repertoires Subject: help for sequence. Date: 26 Nov 1998 01:31:07 -0800 Organization: Laboratory of Medical Genetics Lines: 12 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <3683DFB3.4C9D7C78@ems.hrbmu.edu.cn> Reply-To: fenghc@ems.hrbmu.edu.cn NNTP-Posting-Host: net.bio.net what is the complete sequence of expression plasmid pVG3. Thank you very much. to mail . fenghc@ems.hrbmu.edu.cn From owner-repertoires@net.bio.net Wed Nov 25 22:00:00 1998 Path: biosci!biosci!not-for-mail From: Mike Briley Newsgroups: bionet.molecules.repertoires Subject: International symposium Date: 26 Nov 1998 01:16:55 -0800 Organization: ImagiNET Lines: 9 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <73gpp4$8kr$1@news.imaginet.fr> NNTP-Posting-Host: net.bio.net International symposium Molecular Genetics of Mental Disorders 1-3 December 1999 in Castres, France more details http://www.entretiens-du-carla.com Mike Briley From owner-repertoires@net.bio.net Thu Nov 26 22:00:00 1998 Path: biosci!biosci!not-for-mail From: Shu-Kun Lin Newsgroups: bionet.molecules.repertoires Subject: From my unfortunate experience with Springer ... Date: 27 Nov 1998 07:34:19 -0800 Organization: University of Basel, Switzerland Lines: 44 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <6279n6$79b@mserv1.dl.ac.uk> Reply-To: Shu-Kun Lin NNTP-Posting-Host: net.bio.net My dear colleagues: During recent months of suffering from Springer Verlag's lawsuit regarding the journal MOLECULES (http://mdpi.org/molecules/), I thought a lot and concluded that the internet publication and electronic conference really give all of our scientists unprecedented freedom of press and we all should love it: Now the technical part of publication is extremely easy and cheap. Every scientist can be a publisher himself. I tell you frankly we published 20 issues of MOLECULES (Vol.2, vol. 3) by ourselves with very easy-to-use software. Before that, publication must be done by a publishing company. Now it is not necessary at all. The only remaining part of publication is peer review of the manuscripts, which has been done exclusively by scientists themselves anyway. My MOLECULES vol.2 and 3 were published not by any publishing company. However, I received more supports and I have more manuscripts than I can publish. The quality (layout, etc.) is very good. This is recognized by the fact that all the major abstracting and indexing services covered my two volumes. Therefore, I believe in near future publishing companies will be vanishing. Long live the Internet!! If they want to survive, the only chance might be to become humble database manager, because Internet makes everything related to information nothing but database. >From my very unfortunate experience with Springer Verlag, I would like to tell all of those dear colleagues who plan to launch a new journal, particularly an internet one, think at least twice before collaborating with a "famous" professional publisher, it might be predatory one! I also want to use this chance to protest openly against Springer Verlag. I am not used to this kind of thing but I will fight against this injustice. However, I believe the principles in the world still exist and the basic human rights of free press will be protected. I thank many colleagues who encouraged me. Please rebroadcast this message. Sincerely, Shu-Kun Lin http://www.mdpi.org/lin/ From owner-repertoires@net.bio.net Sun Nov 29 22:00:00 1998 Path: biosci!biosci!not-for-mail From: Luc Van Hijfte Newsgroups: bionet.molecules.repertoires Subject: Position robotics engineer Date: 30 Nov 1998 06:57:07 -0800 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 42 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <73tsej$dc0$1@mserv2.dl.ac.uk> NNTP-Posting-Host: net.bio.net Synthelabo, 3rd french largest pharmaceutical group, which employs 8500 people, has achieved a turnover of 11,7 billion francs in 1997, 14% of which is invested in its research activities. The Research Division, with a staff of 1350 specialised researchers, develops highly innovative drugs, mainly in the areas of central nervous system, cardiovascular and internal medicine. Synthelabo Biomoleculaire, the centre of new drug discovery technologies, located in Strasbourg, France, performs research to advance the use of high trough-put screening, combinatorial chemistry, molecular biology and structural biology toward the rapid generation of leads for new therapeutic targets emerging from the human genome. We have an immediate opening for a Robotic Engineer. Your responsibilities will include the maintenance, optimisation and design of robotic systems for automated chemical synthesis, in close collaboration with our chemists. The ideal candidate will have a Ph.D. in mechanical or chemical engineering, with at least 3 years of relevant postdoctoral experience. Working knowledge of liquid handling robots and strong programming experience is essential. The position requires excellent communication skills, flexibility, creativity and the ability to work in multidisciplinary project-focused teams. Please send your CV to Synthelabo Biomoleculaire, Human Resources Department, 16, rue d'Ankara, 67080 Strasbourg (France). Informal inquiries can be addressed by email to : vanhijftel@synbio.tpgnet.net ########################################### Luc Van Hijfte, Ph.D. Department head, Combinatorial Chemistry Synthelabo Biomoleculaire 16 rue d'Ankara 67080 Strasbourg Phone : 0388608758 Fax : 0388459075 ########################################### From owner-repertoires@net.bio.net Mon Nov 30 22:00:00 1998 Path: biosci!biosci!not-for-mail From: Shu-Kun Lin Newsgroups: bionet.molecules.repertoires Subject: MDPI's Molecules and Springer's "Molecules Online" Date: 1 Dec 1998 02:27:21 -0800 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 115 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <73ub71$lap$1@mserv2.dl.ac.uk> NNTP-Posting-Host: net.bio.net Dear colleagues: Thanks for the concern regarding my trouble from Springer. In answering many requests, I would like to put the open letter to Springer's "Molecules Online" editor here, where I have presented some simple facts. I already contacted with Springer's "Molecules Online" editor before. But he never gave me a reply. I am very busy and do not really have time to bother anyone or to prepare such long letter to anybody. Thanks again. Shu-Kun Lin --------- Open letter to the editor of Springer's "Molecules Online" http://www.mdpi.org/molecules/protest/indexp.htm Dear Dr. Stephen Hanessian: In order to protect the basic freedom of press and information exchange of so many of our fellow scientists who are the authors, the subscribers, and the supporters of our journal Molecules (vol.3, 1998, http://www.mdpi.org/molecules/) from further damage by Springer Verlag, on a very basic ethical ground and in light of the following reason, please consider whether you resign from the editor-in-chief position of Springer's "Molecules Online". MDPI's Molecules and Springer's "Molecules Online" could have been published separately as two independent journals. However, Springer created the problem by insisting that "Molecules Online" is not a separate journal, and started this year to launch it as a "continuation" of our journal Molecules. Springer claimed in a hegemonic manner that MDPI's Molecules is not allowed to publish and only its journal can publish. The fact is that Molecules is not Springer's trademark of publication. (History will witness that Springer will finally loss this case generated by itself because it violated the basic human rights of free press.) Please also be reminded another simple fact that the founding editor (Dr. Shu-Kun Lin) of Molecules is still alive, active and has been continuously and successfully editing this journal and has never invited anybody to replace him. It has been demonstrated that I have credit to run Molecules, even though I never pretended to have any great achievement in organic synthesis (I only imagined a little bit to have chance to win a Nobel prize, I mean Nobel Peace Prize, due to my novel theoretical work on diversity assessment, my practical work on diversity preservation of both substance sample and information, and my strong advocacy on press freedom). Molecules is started as the first journal to support the preservation of molecular diversity by samples deposit. It has been treated as MDPI's official journal since 1995 as you may find from MDPI paid advertisement published in scientific journals in 1995, including several issues of "Synthesis" in 1995. We also used MDPI fund to pay all the editorial work, including paying a guest editor. Springer never paid me a penny during the whole year of 1996. Springer only provided publication service for the journal edited by me and for vol.1 publication only, before Springer unilaterally and suddenly terminated the contract of publication service at the end of 1996. Because of the ruthless harassment from Springer, we cannot make our papers published by MDPI in 1997 and 1998 available to the public for months and cannot publish any of the recently accepted manuscripts. During recent six months, Springer even insisted on deleting all of our papers published already in Molecules vol.2, 1997 and vol.3, 1998. Published papers are very much like born babies. Can you put them back into their mother's body? From this case, as you might have also realized, Springer's present executive in this division of publication has no respect on our scientists' basic rights. Like many of your colleagues in Basel, Switzerland, I have attended your lectures and I like them very much. You are a good scientist. You should have no difficulty to launch your own new journal successfully. To our scientists in organic chemistry, Springer might be a great company because it was the publisher of Beilstein database (This database is definitely no longer published by Springer now). However, it is not so great as to risk one's reputation and to let Springer continue to use your name and to put you on a position only to try to destroy your fellow scientists' established journal Molecules. The case of Molecules already caused public anger against Springer. My colleagues and I will greatly appreciate it if you support our Molecules instead of collaborating with Springer to destroy it. We want to go on with our unique publication policy of Molecules and continue our great efforts to preserve and exchange chemical samples and experimental data. With best regards, Sincerely, Dr. Shu-Kun Lin Editor-in-Chief, Molecules (ISSN 1420 3049) http://www.mdpi.org/lin/ Basel, 30 November 1998, via e-mail From owner-repertoires@net.bio.net Mon Nov 30 22:00:00 1998 Path: biosci!biosci!not-for-mail From: BIOSCI Administrator Newsgroups: bionet.molecules.repertoires Subject: BIOSCI/bionet miniFAQ & Fundraiser Date: 1 Dec 1998 02:21:38 -0800 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 236 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <199811281000.CAA10523@net.bio.net> NNTP-Posting-Host: net.bio.net (LAST REVISION: 30-JUL-95) This BIOSCI "miniFAQ" is designed to answer the questions that come up the *most frequently*. The main BIOSCI FAQ (Frequently Asked Questions) is accessible on the World Wide Web at URL http://www.bio.net/. If you can not find an answer to your question in this or other documentation, the BIOSCI technical support staff answers e-mail queries sent to biosci-help@net.bio.net We can only answer questions about the use of the newsgroups and mailing lists. We unfortunately do not have the staff to do Internet information searches or answer scientific questions. Please post those to the appropriate BIOSCI/bionet newsgroups. Contents: -------- 0) BIOSCI NEEDS YOUR SUPPORT!! 1) Using the WWW to access the BIOSCI/bionet newsgroups. 2) What to do about "spams," i.e., junk mail, ads, etc. 3) Examples of subscribing and unsubscribing to the mailing lists. 4) The BIOSCI user address and research interest directory. 0) BIOSCI NEEDS YOUR SUPPORT!! ------------------------------ BIOSCI's government funding has been expended, and we are now operating solely from advertising revenue that we have raised from our Web site at http://www.bio.net/. We need just a few minutes of your time to help us serve you. You can do two important things which will take very little time for you individually and will immensely help us continue to help you. First, please use our WWW system at http://www.bio.net/ to access the archives. You can post or reply to messages via your Web browser as described in item #1 below. Your usage helps attract sponsors. If you contact any of our sponsors, please be sure to thank them for supporting BIOSCI. It is critical for them to get this feedback if they are to continue their sponsorship for the long term. Second, if you work for a company or organization that provides products or services of interest to the biology community, please pass this message on to your marketing or marketing communications department or other appropriate group. Please ask them to help support BIOSCI by sponsoring our Web site and explain the uses and benefits of the system to the biology community. If they are interested, they can then contact us for further information at our tech support address, biosci-help@net.bio.net. 1) Using the WWW to access the BIOSCI/bionet newsgroups. -------------------------------------------------------- As of 10 December 1995, all BIOSCI/bionet full newsgroups are accessible through the World Wide Web (WWW) at URL http://www.bio.net. One can read and reply publicly or privately to both recent postings and archived messages through one's Web browser if it is configured properly to send e-mail. Each newsgroup is equipped with its own WAIS index. The main BIOSCI home page also has access to the BIO-JOURNALS Table of Contents database WAIS index and the BIOSCI user address database described in another item further below. 2) What to do about "spams," i.e., junk mail, ads, etc. ------------------------------------------------------- BIOSCI is a set of parallel USENET newsgroups (the "bionet" groups), mailing lists, and a hypermail archive at URL http://www.bio.net/. The same postings are distributed on all media (except for a small number of mailing-list-only groups at net.bio.net). Unfortunately it is becoming a despicable practice on the Internet (by a few people out to make a fast buck) to do automated mass postings to thousands of newsgroups and mailing lists. These attempts to grab free advertising are refered to as "spams" in the usual, somewhat boneheaded, net terminology. USENET is more susceptible to this practice, and many spams originate on the USENET groups and then are passed on to the mailing lists. However, spammers also get lists of mailing addresses and hit these too, so neither medium is immune. What should you do personally if you get junk mail? --------------------------------------------------- Just delete it and move on without reading it further. Filing a protest is becoming increasingly useless because spammers are often disguising the addresses where the messages are sent from. Unless you really understand Internet mail systems, your attempt at protest by sending replies to the message will often end up being sent to the address of an innocent person that the spammer is victimizing. What can BIOSCI/bionet do to protect its newsgroups? ---------------------------------------------------- The only solution currently available is to moderate the newsgroup. If this newsgroup is already moderated, then you are in good shape. Moderation protects the USENET distribution from about 95% of the spams that are being sent to date and protects the mailing lists completely. Moderation means, however, that someone has to take the time to review each message before it goes out. We have set up software here that simply allows the moderator to forward to an address at net.bio.net messages that (s)he wishes to have distributed. This takes no more time than that needed to read the message and pass it on, say about 1 min. per message. Most newsgroups currently have a discussion leader who is responsible for their newsgroup. The discussions leaders and their e-mail addresses are listed in the BIOSCI Information Sheet which is available on the Web at http://www.bio.net/. If a newsgroup is being hit with too many junk postings, please contact the discussion leader for that group and see if there is interest in moderating the group. Please do not assume that by simply posting a complaint to the newsgroup itself, anyone on the BIOSCI staff will act on your complaint. With close to 100 newsgroups to run, the BIOSCI staff has to rely on the discussion leaders of each newsgroup to report problems directly to us at biosci-help@net.bio.net. We will moderate any of our newsgroups if the discussion leader tells us that the readership of the group wishes to do so and if a moderator is willing to do the work. For most BIOSCI/bionet groups, this entails only a few minutes of work each day. Moderating a newsgroup will resolve probably 95% of the junk postings on the USENET distribution. Unfortunately there are easy ways for determined spammers to override the moderation mechanism on USENET, but we can protect our e-mail subscribers from unwanted postings if the newsgroup is moderated. You can also access our newsgroups over the WWW at URL http://www.bio.net. While this Web interface will not stop spammers from trying to post to the groups, this will give you yet another way, besides using USENET news, to keep the junk out of your personal mail files. For those of you with local USENET news systems, the Web interface will also give you faster access to new newsgroups and recent postings. 3) Examples of subscribing and unsubscribing to the mailing lists. ------------------------------------------------------------------ PLEASE NOTE: The BIOSCI management does NOT act on subscription/unsubscription requests that are posted improperly to the newsgroups and mailing lists. People who do this only bother everyone on the lists to no avail. Please be sure to follow the proper procedures below. Gory details are in the BIOSCI Information sheets on the Web at http://www.bio.net. Below we give an example utilizing the METHODS-AND-REAGENTS list at both of our two BIOSCI sites: Users in the Americas and Pacific Rim countries who use the BIOSCI ------------------------------------------------------------------ node at computer net.bio.net: ---------------------------- A) Determine the "listname" which is the <=8 character mail address ^^^^^^^^^^^^^ for the group. These can be found in the BIOSCI Info. Sheet. For the METHODS-AND-REAGENTS group the mailing address is methods@net.bio.net. The listname is the portion of the address to the left of the @ sign, i.e., "methods". The listname is used with the "subscribe" and "unsubscribe" commands illustrated below. B) Mail all commands in the body of a mail message addressed to biosci-server@net.bio.net. Do NOT send commands to the newsgroup posting addresses! Leave the Subject: line blank, any text on it will be ignored. C) In the body of your message put one or more of the following commands with an "end" command on the last line, e.g., subscribe methods unsubscribe methods end Do NOT put your e-mail address or other text on these lines. The server only allows you to cancel your subscription if the address on your mail header matches the address on our mailing list. Please ask for help at biosci-help@net.bio.net if your address has changed, e.g., if you know you are on the list but the server tells you that you are not a member. Users in Europe, Africa, and Central Asia who use the BIOSCI node at -------------------------------------------------------------------- computer daresbury.ac.uk (also known as dl.ac.uk): ------------------------------------------------- To subscribe and unsubscribe to/from the BIOSCI lists, you need to specify the full USENET newsgroup name with "bionet-news." prepended. The USENET newsgroup names are listed in the BIOSCI Information sheet on the Web at http://www.bio.net/. For the METHODS-AND-REAGENTS list the USENET newsgroup name is bionet.molbio.methds-reagnts, thus the appropriate commands are sub bionet-news.bionet.molbio.methds-reagnts unsub bionet-news.bionet.molbio.methds-reagnts These commands are included in a message addressed to mxt@dl.ac.uk, NOT to the newsgroup mailing addresses. As usual, include the text in the body of the message as text on the Subject: line is ignored. To unsubscribe from all the lists at the UK node, use unsub bionet-news Please note that if the address in the list is different than the one in your mail message header, you will not be able to unsubscribe by this method. If you have problems, please mail biosci@daresbury.ac.uk. 4) The BIOSCI user address and research interest directory. ----------------------------------------------------------- Please take this opportunity to add your name, address, and research interest information to the BIOSCI User Address Database if you have not already done so. You can fill out the address form directly through our Web page at URL http://www.bio.net/adrform.html. The address database is reindexed nightly for WWW access (the URL is http://www.bio.net/). If you are not directly on the Internet but can reach it by e-mail, please use our waismail server to access the user directory. waismail use is described above. You can also request a user address form by e-mail from biosci-help@net.bio.net. Please check your database entry from time-to-time to see if your address information is still up-to-date. Because of our limited personnel resources, we ask that you resubmit a *complete* form to revise your entry; we only replace complete entries and do not have resources to edit old forms. From owner-repertoires@net.bio.net Mon Nov 30 22:00:00 1998 Path: biosci!biosci!not-for-mail From: biofilter@millipore.com (Millipore Corporation) Newsgroups: bionet.molecules.repertoires Subject: Millipore introduces ZipTips, pipette tips for sample preparation Date: 1 Dec 1998 09:48:13 -0800 Organization: @Home Network Lines: 23 Sender: daemon@net.bio.net Approved: A.Wallace@Queens-Belfast.AC.UK Distribution: world Message-ID: <36641120.94654330@news.comcastwork.com> NNTP-Posting-Host: net.bio.net Millipore introduces ZipTips, pipette tips for sample preparation Now desalt a few microliters of femtomole-level peptide in under 60 seconds with Millipore's new ZipTip pipette tips for sample preparation. ZipTip C18 is a 10 microliter pipette tip with 0.6 ml of C18 resin fixed at its end such that there is no dead volume. In operation, ZipTip is placed on a standard single or multi-channel pipettor. The sample is aspirated and dispensed through the resin to bind and wash peptides or small proteins. Elution is in 1 - 4 uL of acetonitrile/water. ZipTip is ideal for preparing samples for Mass Spectroscopy or other analytical techniques. Unlike other methods, ZipTip saves time by providing a fast, ready-to-use device for off-line sample preparation. For more product specs, user guides, tech notes and ordering information please see: http://www.millipore.com/analytical/technote/ziptip/